Khiron Life Sciences Corp.
KHRNH.V
TSX
| 09/30/2022 | 06/30/2022 | 03/31/2022 | 12/31/2021 | 09/30/2021 | |
|---|---|---|---|---|---|
| Revenue | 12.65M | 12.85M | 11.63M | 10.20M | 9.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.65M | 12.85M | 11.63M | 10.20M | 9.25M |
| Cost of Revenue | 7.43M | 7.46M | 6.59M | 5.11M | 1.53M |
| Gross Profit | 5.22M | 5.39M | 5.03M | 5.09M | 7.71M |
| SG&A Expenses | 17.51M | 18.50M | 19.90M | 20.48M | 20.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.32M | 27.49M | 27.62M | 26.56M | 22.67M |
| Operating Income | -13.67M | -14.64M | -15.99M | -16.36M | -13.42M |
| Income Before Tax | -24.48M | -24.49M | -26.67M | -26.73M | -12.64M |
| Income Tax Expenses | -294.90K | -389.90K | -368.20K | -369.00K | 70.30K |
| Earnings from Continuing Operations | -24.19 | -24.10 | -26.30 | -26.37 | -12.71 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.19M | -24.10M | -26.30M | -26.37M | -12.71M |
| EBIT | -13.67M | -14.64M | -15.99M | -16.36M | -13.42M |
| EBITDA | -12.62M | -13.59M | -15.01M | -15.48M | -12.65M |
| EPS Basic | -0.13 | -0.13 | -0.15 | -0.16 | -0.08 |
| Normalized Basic EPS | -0.04 | -0.05 | -0.06 | -0.06 | -0.05 |
| EPS Diluted | -0.13 | -0.14 | -0.15 | -0.16 | -0.09 |
| Normalized Diluted EPS | -0.04 | -0.05 | -0.06 | -0.06 | -0.05 |
| Average Basic Shares Outstanding | 759.37M | 721.87M | 686.46M | 657.78M | 609.14M |
| Average Diluted Shares Outstanding | 759.37M | 721.87M | 686.46M | 657.78M | 609.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
